156 related articles for article (PubMed ID: 18709566)
1. Pain and u-shaped dose responses: occurrence, mechanisms, and clinical implications.
Calabrese EJ
Crit Rev Toxicol; 2008; 38(7):579-90. PubMed ID: 18709566
[TBL] [Abstract][Full Text] [Related]
2. Modulation of the epileptic seizure threshold: implications of biphasic dose responses.
Calabrese EJ
Crit Rev Toxicol; 2008; 38(6):543-56. PubMed ID: 18615309
[TBL] [Abstract][Full Text] [Related]
3. U-shaped dose response in behavioral pharmacology: historical foundations.
Calabrese EJ
Crit Rev Toxicol; 2008; 38(7):591-8. PubMed ID: 18709567
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological enhancement of neuronal survival.
Calabrese EJ
Crit Rev Toxicol; 2008; 38(4):349-89. PubMed ID: 18432420
[TBL] [Abstract][Full Text] [Related]
5. Drug therapies for stroke and traumatic brain injury often display U-shaped dose responses: occurrence, mechanisms, and clinical implications.
Calabrese EJ
Crit Rev Toxicol; 2008; 38(6):557-77. PubMed ID: 18615310
[TBL] [Abstract][Full Text] [Related]
6. Alzheimer's disease drugs: an application of the hormetic dose-response model.
Calabrese EJ
Crit Rev Toxicol; 2008; 38(5):419-51. PubMed ID: 18568864
[TBL] [Abstract][Full Text] [Related]
7. Dose-response features of neuroprotective agents: an integrative summary.
Calabrese EJ
Crit Rev Toxicol; 2008; 38(4):253-348. PubMed ID: 18432419
[TBL] [Abstract][Full Text] [Related]
8. An assessment of anxiolytic drug screening tests: hormetic dose responses predominate.
Calabrese EJ
Crit Rev Toxicol; 2008; 38(6):489-542. PubMed ID: 18615308
[TBL] [Abstract][Full Text] [Related]
9. Addiction and dose response: the psychomotor stimulant theory of addiction reveals that hormetic dose responses are dominant.
Calabrese EJ
Crit Rev Toxicol; 2008; 38(7):599-617. PubMed ID: 18709568
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological assessment of the rat formalin test utilizing the clinically used analgesic drugs gabapentin, lamotrigine, morphine, duloxetine, tramadol and ibuprofen: influence of low and high formalin concentrations.
Munro G
Eur J Pharmacol; 2009 Mar; 605(1-3):95-102. PubMed ID: 19168051
[TBL] [Abstract][Full Text] [Related]
11. Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55,940 are absent in CB1(-/-) and not CB2(-/-) mice in models of acute and persistent pain.
Sain NM; Liang A; Kane SA; Urban MO
Neuropharmacology; 2009 Sep; 57(3):235-41. PubMed ID: 19538975
[TBL] [Abstract][Full Text] [Related]
12. Animal models of nociception.
Le Bars D; Gozariu M; Cadden SW
Pharmacol Rev; 2001 Dec; 53(4):597-652. PubMed ID: 11734620
[TBL] [Abstract][Full Text] [Related]
13. Dose-response of minor analgesics in acute pain.
Li Wan Po A
Br J Clin Pharmacol; 2007 Mar; 63(3):268-70. PubMed ID: 16869818
[No Abstract] [Full Text] [Related]
14. Human experimental pain models in drug development: translational pain research.
Arendt-Nielsen L; Curatolo M; Drewes A
Curr Opin Investig Drugs; 2007 Jan; 8(1):41-53. PubMed ID: 17263184
[TBL] [Abstract][Full Text] [Related]
15. P-glycoprotein efflux transporter activity often displays biphasic dose-response relationships.
Calabrese EJ
Crit Rev Toxicol; 2008; 38(5):473-87. PubMed ID: 18568867
[TBL] [Abstract][Full Text] [Related]
16. Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway.
Gunthorpe MJ; Chizh BA
Drug Discov Today; 2009 Jan; 14(1-2):56-67. PubMed ID: 19063991
[TBL] [Abstract][Full Text] [Related]
17. Antinociceptive properties of the hydroalcoholic extract, fractions and compounds obtained from the aerial parts of Baccharis illinita DC in mice.
Freitas CS; Baggio CH; Dos Santos AC; Mayer B; Twardowschy A; Luiz AP; Marcon R; Soldi C; Pizzolatti MG; Dos Santos EP; Marques MC; Santos AR
Basic Clin Pharmacol Toxicol; 2009 Apr; 104(4):285-92. PubMed ID: 19281601
[TBL] [Abstract][Full Text] [Related]
18. Differences in the sensitivity of behavioural measures of pain to the selectivity of cyclo-oxygenase inhibitors.
Huntjens DR; Spalding DJ; Danhof M; Della Pasqua OE
Eur J Pain; 2009 May; 13(5):448-57. PubMed ID: 18774319
[TBL] [Abstract][Full Text] [Related]
19. Predicting therapeutic efficacy - experimental pain in human subjects.
Chizh BA; Priestley T; Rowbotham M; Schaffler K
Brain Res Rev; 2009 Apr; 60(1):243-54. PubMed ID: 19168094
[TBL] [Abstract][Full Text] [Related]
20. Evidence of TRPV1 receptor and PKC signaling pathway in the antinociceptive effect of amyrin octanoate.
Marcon R; Luiz AP; Werner MF; Freitas CS; Baggio CH; Nascimento FP; Soldi C; Pizzolatti MG; Santos AR
Brain Res; 2009 Oct; 1295():76-88. PubMed ID: 19646975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
